Within-Trial Evaluation of Medical Resources, Costs, and Quality of Life Among Patients With Type 2 Diabetes Participating in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).
Shelby D ReedYanhong LiHelen A DakinFrauke BeckerShelby D ReedStephanie M GustavsonBernt KartmanEric WittbrodtRobert J MentzNeha J PagidipatiM Angelyn BethelAlastair M GrayRury R HolmanAdrian F Hernandeznull nullPublished in: Diabetes care (2019)
Medical costs were lower in the EQW arm than the placebo arm, but total costs were significantly higher once the cost of branded exenatide was incorporated.